• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Medical

Safety study of inhaled alpha1-proteinase inhibitor for CF to begin this year

Grifols has announced that its inhaled alpha1-proteinase inhibitor received orphan drug designation from the FDA in April 2012 and that the company will begin a safety study of the drug by the end of the year. Grifols markets intravenous alpha1-proteinase inhibitor, derived from human plasma, as Prolastin-C as a treatment for alpha1-antitrypsin (AAT) deficiency and is … [Read more...] about Safety study of inhaled alpha1-proteinase inhibitor for CF to begin this year

Results from four Phase 3 studies of GSK’s LAMA/LABA inhaler for COPD

GlaxoSmithKline and Theravance have announced results from four Phase 3 studies of its umeclidinium bromide (UMEC)/vilanterol (VI) combination DPI for the treatment of COPD. The studies include two 24-week efficacy studies and two 24-week active comparator studies comparing UMEC/VI with tiotropium. UMEC is a a long-acting muscarinic antagonist (LAMA) and vilanterol is … [Read more...] about Results from four Phase 3 studies of GSK’s LAMA/LABA inhaler for COPD

Regency launches study of Sprix ketorolac nasal spray

Regency Therapeutics has announced the initiation of the 18-month AMPED (Acute Management of Pain from the Emergency Department) registry study to compare patient response to Sprix ketorolac tromethamine nasal spray used to treat pain in emergency departments to outcomes for patients prescribe oral narcotics. The study will be conducted in 15 hospitals, including the … [Read more...] about Regency launches study of Sprix ketorolac nasal spray

Civitas initiates Phase 2a study of inhaled L-dopa

Civitas Therapeutics has announced the initiation of a Phase 2a clinical trial of its CVT-301 inhaled L-dopa for the treatment of motor fluctuations in patients with Parkinson’s disease. CVT-301 is formulated and delivered using the company's proprietary Arcus dry powder technology. Development of the product is being funded in part by the Michael J. Fox Foundation … [Read more...] about Civitas initiates Phase 2a study of inhaled L-dopa

Savara announces Phase I study results for AeroVanc, funding for Phase 2

Savara Pharmaceuticals has announced positive top-line results from a Phase 1 study of its AeroVanc inhaled dry powder formulation of vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis. According to the company, the study demonstrated that AeroVanc was well tolerated, that clearance of the … [Read more...] about Savara announces Phase I study results for AeroVanc, funding for Phase 2

Alnylam inhaled RSV drug misses primary endpoint in Phase 2b study

Alnylam Pharmaceuticals says that its ALN-RSV01 inhaled RNAi drug failed to meet the primary endpoint of a Phase 2b study, not significantly reducing the incidence of bronchiolitis obliterans syndrome (BOS) at 180 days after infection in lung transplant patients infected with respiratory syncytial virus (RSV) in an “intent-to-treat” (ITTc) analysis, but that it met … [Read more...] about Alnylam inhaled RSV drug misses primary endpoint in Phase 2b study

Insmed to defer Phase 3 study of Arikace in US

According to Insmed, the company has decided to focus on European and Canadian studies of its Arikace liposomal amikacin for inhalation and to put a US Phase 3 study on the back burner. The CLEAR-108 (CLinical Evaluation of ARikace) Phase 3 study of Arikace for the treatment of patients with cystic fibrosis is already underway in Europe and Canada, and Insmed says … [Read more...] about Insmed to defer Phase 3 study of Arikace in US

Boehringer Ingelheim announces results from studies of olodaterol and tiotropium

Boehringer Ingelheim has presented data from studies of olodaterol and tiotropium at the 2012 Annual Meeting of the American Thoracic Society. According to the company, it has now completed its Phase 2 trials of olodaterol, delivered via the Respimat soft mist inhaler, as a monotherapy for COPD, and that Phase 3 trials are also complete. BI is also developing a fixed … [Read more...] about Boehringer Ingelheim announces results from studies of olodaterol and tiotropium

US plan to fight Alzheimer’s includes funding for development of insulin nasal spray

US Health and Human Services Secretary Kathleen Sebelius has announced a national plan to fight Alzheimer’s disease that includes almost $8 million in funding for research related to an insulin nasal spray for the treatment of the disease. An article published in the Archives of Neurology in September 2011 described positive results from the SNIFF (Study of Nasal … [Read more...] about US plan to fight Alzheimer’s includes funding for development of insulin nasal spray

Positive Phase 2b results for Elevation’s glycopyrrolate inhalation solution

Elevation Pharmaceuticals has announced that a Phase 2b study of its EP-101 glycopyrrolate inhalation solution in patients with moderate to severe COPD demonstrated that EP-101 produced statistically significant improvement in lung function compared to placebo after 7 days. The GOLDEN-1 (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) study … [Read more...] about Positive Phase 2b results for Elevation’s glycopyrrolate inhalation solution

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 102
  • Page 103
  • Page 104
  • Page 105
  • Page 106
  • Interim pages omitted …
  • Page 119
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews